Literature DB >> 18221029

Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?

Ferdinando Mannello1.   

Abstract

The matrix metalloproteinases (MMPs), belonging to the family of proteolytic enzymes, are well-known for their ability to degrade the extracellular matrix, and are involved in many aspects of both physiological cellular processes and pathological situations, such as tumor growth, invasion and metastasis. MMPs have been considered prognostic factors in various types of cancer as well as promising targets for cancer therapy. Although preclinical studies of a number of different synthetic MMP inhibitors have been identified as cytostatic and anti-angiogenic agents and have begun clinical testing, the past years have produced a consistent number of disappointments and limited successes. In view of their specific implication in malignant tissues, several natural compounds were utilized, and the results were so satisfactory as to encourage several clinical trials in order to improve efficacy and to reduce the side effect profile. The natural protection against cancer has been receiving a great deal of attention, and the critical examination of previous studies shed light on new information about the source and function of MMPs, focusing the attention on the identification of MMP targets in tumors. This review discusses the current knowledge and research in the field of natural MMP inhibitor as innovative therapeutic intervention in cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18221029     DOI: 10.2174/157489206775246421

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  16 in total

1.  What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Authors:  Ferdinando Mannello
Journal:  BMC Med       Date:  2011-08-11       Impact factor: 8.775

2.  Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9.

Authors:  Athira Omanakuttan; Jyotsna Nambiar; Rodney M Harris; Chinchu Bose; Nanjan Pandurangan; Rebu K Varghese; Geetha B Kumar; John A Tainer; Asoke Banerji; J Jefferson P Perry; Bipin G Nair
Journal:  Mol Pharmacol       Date:  2012-06-28       Impact factor: 4.436

3.  Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.

Authors:  Qi Gao; Yijun Wang; Jiaying Hou; Qizheng Yao; Ji Zhang
Journal:  J Comput Aided Mol Des       Date:  2017-06-16       Impact factor: 3.686

4.  Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research.

Authors:  Ferdinando Mannello; Joseph D Raffetto
Journal:  Am J Transl Res       Date:  2010-11-23       Impact factor: 4.060

Review 5.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

Review 6.  Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.

Authors:  Chen Zhang; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2009-03-31       Impact factor: 5.118

Review 7.  Biological characterizations of [Gd@C82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy.

Authors:  Jie Meng; Xingjie Liang; Xiaoyuan Chen; Yuliang Zhao
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

8.  Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.

Authors:  Guo Li; Kendra M Haney; Glen E Kellogg; Yan Zhang
Journal:  J Chem Inf Model       Date:  2009-01       Impact factor: 4.956

9.  Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells.

Authors:  Huan Meng; Gengmei Xing; Elvin Blanco; Yan Song; Lina Zhao; Baoyun Sun; Xiaoda Li; Paul C Wang; Alexandru Korotcov; Wei Li; Xing-Jie Liang; Chunying Chen; Hui Yuan; Feng Zhao; Zhen Chen; Tong Sun; Zhifang Chai; Mauro Ferrari; Yuliang Zhao
Journal:  Nanomedicine       Date:  2011-09-17       Impact factor: 5.307

Review 10.  The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.

Authors:  László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay
Journal:  Int J Mol Sci       Date:  2012-10-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.